arrow
M

Michelle Haber

UNSW Sydney
H指数:65
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The PLK4 inhibitor RP-1664 demonstrates potent efficacy in neuroblastoma preclinical models through a dual mechanism of sensitivity

PLK4抑制剂RP-1664通过双重敏感性机制在神经母细胞瘤临床前模型中显示出显著疗效

2026-06-130
OAAI
Precision-guided therapy in H3K27-altered diffuse midline glioma

H3K27-改变的弥漫性中线胶质瘤中的精准导向疗法

2026-05-190
OAAI
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma

在多药联合化疗中加入JNK非依赖性药物可改善复发高风险神经母细胞瘤的治疗反应

2025-11-280
PRE
P-glycoprotein as a chemotherapy resistance mechanism and biomarker of poor response in high-risk neuroblastoma
2025-11-010
OA
Polyamine depletion limits progression of acute leukaemia
2025-02-220
PRE
Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma

铜螯合改变中性粒细胞功能以增强神经母细胞瘤的anti-GD2抗体治疗

2024-12-120
OAAI
Golgi-localized Ring Finger Protein 121 is necessary for MYCN-driven neuroblastoma tumorigenesis

高尔基体定位的环指蛋白121是MYCN驱动的神经母细胞瘤肿瘤发生所必需的

2024-10-140
OAAI
Clinical utility of real-time comprehensive molecular profiling in childhood brain tumors
2024-09-050
PRE
Implementing ultra-sensitive, ctDNA-based liquid biopsy for disease monitoring in paediatric tumours
2024-09-050
PRE
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis

转录共阻遏物Runx1t1对于MYCN驱动的神经母细胞瘤肿瘤发生至关重要

2024-07-111
OAAI
Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing

单碱基平铺屏幕揭示了PspCas13b的设计原理,用于有效和脱靶无RNA沉默

2024-07-012
OAAI
PRECISION GUIDED THERAPY PROVIDES CLINICAL BENEFIT IN H3K27-ALTERED DIFFUSE MIDLINE GLIOMA
2024-06-180
OAAI
Precision-guided treatment in high-risk pediatric cancers
2024-06-067
OAAI